Efficacy of edaravone and dexborneol combined with citicoline sodium on treatment of patients with acute progressive cerebral infarction
Li Wanzhen
Yang Song
Wu Li
Guo Fuqiang
Abstract：Objective To investigate the clinical efficacy of edaravone and dexborneol combined with citicoline sodium in the treatment of the patients with acute progressive cerebral infarction.Methods A total of 103 patients who were diagnosed with acute progressive cerebral infarction and treated in the Department of Neurology of Chengdu Shuangnan Hospital between January 2021 and August 2024 were enrolled in the study and divided into two groups by computer-generated randomization.The control group with 51 cases was treated with citicoline sodium monotherapy,and the observation group with 52 cases was given combination therapy of citicoline sodium and edaravone dexborneol.The differences in clinical efficacy,oxidative stress response,inflammation level,and drug safety between the two groups were evaluated.Results The effective rate of the observation group was 90.38% (47/52),higher than 74.51% (38/51)of the control group(χ2=4.499,P<0.05).The reactive oxygen species(ROS)and malondialdehyde(MDA)levels of the two groups were lower after the treatment than before the treatment,while the superoxide dismutase(SOD)levels were higher after the treatment than before the treatment.The ROS and MDA levels of the observation group were respectively(451.67±46.67)μmol·L-1 and(4.16±0.62)nmol·L-1,lower than(546.19±41.78)μmol·L-1 and(5.34±0.54)nmol·L-1;the SOD level of the observation group was(101.64±8.77)U·mL-1,higher than(86.54±8.56)U·mL-1 of the control group(t=10.834,10.292,8.841,all P<0.05).The interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and high-sensitivity C-reactive protein(hs-CRP)levels of the two groups were lower after the treatment than before the treatment.The IL-6,TNF-α,and hs-CRP levels of the observation group were respectively(16.78±3.78)ng·L-1,(18.54±2.43)ng·L-1,and(5.34±1.37)mg·L-1,lower than(24.67±4.89)ng·L-1,(23.77±2.65)ng·L-1,and(7.25±1.23)mg·L-1 of the control group(t=9.172,10.443,7.440,all P<0.05).The incidence of adverse reactions was 15.69% (8/51)in the control group and 13.46% (7/52)in the observation group,and there was no significant difference between the two groups(χ2=0.102,P>0.05).Conclusion The combination of edaravone and dexborneol with citicoline sodium demonstrates favorable clinical efficacy in treating acute progressive cerebral infarction.It improves oxidative stress markers,reduces inflammatory responses,and exhibits a favorable safety profile.
Keywords：Edaravone and dexborneolCiticoline sodiumAcute progressive cerebral infarctionInflammatory factorOxidative stress
Publication Date：2025-07-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 581-584 )